- HOME >
- GRADUATE >
- Human Sciences >
Dermatology
| Master's Program | Human Sciences, Graduate School of Medicine |
|---|---|
| Doctor's Program | Medical Science Division, Department of Medical Science, Graduate School of Medicine, Science and Technology |
| Professor | OKUYAMA Ryuhei |
|---|---|
| Associate Professor | KINIWA Yukiko, ASHIDA Atsuko |
| Senior Assistant Professor | OGAWA Eisaku, NAKAMURA Kenta |
| Assistant Professor | OMODAKA Toshikazu, TAKAZAWA Yuko, MIKOSHIBA Asuka |
E-mail ： derma(at)shinshu-u.ac.jp
※ Change (at) to @ when you send an e-mail.
Our main projects are the diagnostic method, evaluation method of disease status and new treatment method of malignant melanoma. Because progressed melanoma is difficult to cure, early diagnosis and treatment are very important for patients. Sometimes, it is difficult to distinguish the early melanoma from the benign pigmented nevus. We aim to establish the new diagnosis methods using photographs and a noninvasive method using the nail pieces. Today, immune checkpoint inhibitors（ICI） and molecular target therapy are often used for the patients suffered from progressed melanoma. We search for ICI effect predictors. We also develop virotherapy againt melanoma in collaboration with the Institute of Medical Scinence, The University of Tokyo.
Since malignant melanoma is one of the aggressive cancers, once it progress, complete remission is difficult. Even using immune checkpoint blockade, objective response rate is up to 30%. We hope that outcomes of our study contribute for improvement both of early diagnosis and treatment of advanced melanoma.
1. Meling MT, Kiniwa Y, Ogawa E, Sato Y, Okuyama R. Increased expression of secreted protein acidic and rich in cysteine and tissue inhibitor of metalloproteinase-3 in epidermotropic melanoma metastasis. J Dermatol. 2021;48:1772-1779.
2. 奥山 隆平, 藤堂 具紀. Cutting-edge medicine 橋渡し188bet体育_188bet备用网址の推進 悪性黒色腫に対する最新ウイルス療法 T-hIL12の医師主導治験. Precision Medicine. 3巻12号 Page1081-1084(2020.11).
3. Nakamura K, Kiniwa Y, Okuyama R. CCL5 production by fibroblasts through a local renin-angiotensin system in malignant melanoma affects tumor immune responses. J Cancer Res Clin Oncol. 2021;147:1993-2001.
4. Kiniwa Y, Nakamura K, Mikoshiba A, Ashida A, Akiyama Y, Morimoto A, Okuyama R. Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation. BMC Cancer. 2021;21:287.
5. Omodaka T, Minagawa A, Okuyama R. Ultraviolet-related skin cancers distribute differently on the face surface. Br J Dermatol. 2021;185:205-207.
6. Miyake T, Minagawa A, Ito S, Yokokawa Y, Wakamatsu K, Okuyama R. Utility of Melanin Degradation Products in the Nail for Diagnosing Nail Apparatus Melanoma. Acta Derm Venereol. 2021;101:adv00387.
7. Minagawa A, Koga H, Sano T, Matsunaga K, Teshima Y, Hamada A, Houjou Y, Okuyama R. Dermoscopic diagnostic performance of Japanese dermatologists for skin tumors differs by patient origin: A deep learning convolutional neural network closes the gap. J Dermatol. 2021;48:232-236.
8. Sato Y, Ogawa E, Okuyama R. Role of Innate Immune Cells in Psoriasis. Int J Mol Sci. 2020;21:6604.
9. Mikoshiba A, Ashida A, Sakaizawa K, Kiniwa Y, Okuyama R. Detecting copy number alterations of oncogenes in cell-free DNA to monitor treatment response in acral and mucosal melanoma. J Dermatol Sci. 2020;97:172-178.
10. Edamitsu T, Taguchi K, Kobayashi EH, Okuyama R, Yamamoto M. Aryl Hydrocarbon Receptor Directly Regulates Artemin Gene Expression. Mol Cell Biol. 2019;39:e00190-19.
